LIPANTHYL SUPRA -- SUPRABIODOSTĘPNA POSTAĆ FENOFIBRATU. POSTĘP W TERAPII DYSLIPIDEMII.

Cardiovascular disease which develops on the basis of atherosclerosis is the main cause of mortality and morbidity in adults and is a huge financial burden. The very beginning of dyslipidemia modern therapy was discovery of fibrates and statins. Fenofibrate is a major representant of the fibrate drug class that is widely used not only in monotherapy but also in combined therapy. There are several formulations of fenofibrat, among them the modern suprabioavailable tablet, with contains 160 and 215 mg of active substance. The new formulation combines micronisation technology with a new microcoating process. Suprabioavailable tablet provides more reliable and predictable drug absorption. In comparison to other fenofibrate formulations, suprabioavailable tablet absorption is less dependent from food effect. Dissolution of tablets is much faster then other formulations. In those conditions lower dose of fenofibrate provides equivalent pharmacokinetic parameters. Clinical trials have proved, that Fenofibrate inhibits significantly progression of atherosclerosis and reduces a risk of cardiovascular events especially in diabetic patients and patients with metabolic syndrome. Suprabioavailable fenofibrate is a safety and well tolerated drug. [ABSTRACT FROM AUTHOR]